Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading SLBT daily closes…
Loading price history…
Pipeline assets
CD-19 Armed-T therapy
Preclinical · ActiveModality: cell therapy (engineered T cells armed with bispecific antibodies)
Aliases CD-19 Armed-T
Target CD19
Partnerships CytoArm Co., Ltd (perpetual, irrevocable, royalty-bearing, exclusive license to CD-19 Armed-T patent applications and know-how)
Indications
Blood cancers (CD19)(Preclinical)
Catalysts
— first quarter of 2027
Status note Preclinical. FDA INTERACT meeting written responses received January 6, 2026; company addressing comments and completing nonclinical/manufacturing work; pre-IND meeting planned before filing.
Partnerships Ji Yan Biomedical (JY BioMed; global exclusive licenses for pancreatic and brain cancer GDT cell therapy products; up to $38M milestones, 7%/10% royalties)
Indications
Pancreatic cancer(Preclinical)
Brain cancer(Preclinical)
Catalysts
— third quarter of 2027
Status note Discovery and preclinical phases completed 2024. IND-enabling GLP toxicology studies pending clinical-grade material; orphan-drug designation request declined March 2026 with request for additional nonclinical data.
Per-asset detail extracted from the 20-F filed 2026-06-18. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.